Fortress Biotech, Inc.

NasdaqCM:FBIO Stock Report

Market Cap: US$34.6m

Fortress Biotech Past Earnings Performance

Past criteria checks 0/6

Fortress Biotech's earnings have been declining at an average annual rate of -13.5%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 19.9% per year.

Key information

-13.5%

Earnings growth rate

6.3%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate19.9%
Return on equity-9,713.5%
Net Margin-81.3%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Dec 29
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Aug 18
There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Aug 11

David Jin is the new finance chief of Fortress Biotech

Jul 22

Is Fortress Biotech (NASDAQ:FBIO) Using Debt Sensibly?

Jan 11
Is Fortress Biotech (NASDAQ:FBIO) Using Debt Sensibly?

Fortress Biotech (NASDAQ:FBIO) Has Debt But No Earnings; Should You Worry?

Sep 28
Fortress Biotech (NASDAQ:FBIO) Has Debt But No Earnings; Should You Worry?

Does Fortress Biotech (NASDAQ:FBIO) Have A Healthy Balance Sheet?

Jun 04
Does Fortress Biotech (NASDAQ:FBIO) Have A Healthy Balance Sheet?

Is Fortress Biotech (NASDAQ:FBIO) Using Too Much Debt?

Mar 04
Is Fortress Biotech (NASDAQ:FBIO) Using Too Much Debt?

When Will Fortress Biotech, Inc. (NASDAQ:FBIO) Turn A Profit?

Feb 06
When Will Fortress Biotech, Inc. (NASDAQ:FBIO) Turn A Profit?

Read This Before Buying Fortress Biotech, Inc. (NASDAQ:FBIO) Shares

Jan 11
Read This Before Buying Fortress Biotech, Inc. (NASDAQ:FBIO) Shares

Fortress Biotech founded Cyprium's CUTX-101 nabs accelerated review for copper metabolism disorder

Dec 15

Is Fortress Biotech, Inc. (NASDAQ:FBIO) Popular Amongst Insiders?

Dec 15
Is Fortress Biotech, Inc. (NASDAQ:FBIO) Popular Amongst Insiders?

Health Check: How Prudently Does Fortress Biotech (NASDAQ:FBIO) Use Debt?

Nov 19
Health Check: How Prudently Does Fortress Biotech (NASDAQ:FBIO) Use Debt?

Fortress Biotech EPS misses by $0.02, misses on revenue

Nov 09

Revenue & Expenses Breakdown
Beta

How Fortress Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:FBIO Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2385-69910
30 Sep 2362-781000
30 Jun 2363-961080
31 Mar 2364-921130
31 Dec 2276-951140
30 Sep 2278-971130
30 Jun 2282-931050
31 Mar 2281-74960
31 Dec 2169-65870
30 Sep 2164-38750
30 Jun 2153-33680
31 Mar 2144-43630
31 Dec 2046-47610
30 Sep 2043-576024
30 Jun 2043-545939
31 Mar 2043-545858
31 Dec 1937-405681
30 Sep 1934-455683
30 Jun 1930-515487
31 Mar 1927-535386
31 Dec 1827-735387
30 Sep 18-107-613877
30 Jun 18-65-694573
31 Mar 18-22-724869
31 Dec 1717-654952
30 Sep 17155-745749
30 Jun 17109-604741
31 Mar 1761-553936
31 Dec 1616-553335
30 Sep 164-503230
30 Jun 163-553033
31 Mar 161-492629
31 Dec 151-482230
30 Sep 151-401825
30 Jun 151-271316
31 Mar 151-251215
31 Dec 140-201010
30 Sep 140-261014
30 Jun 140-301017
31 Mar 140-361022
31 Dec 130-371026
30 Sep 130-361024

Quality Earnings: FBIO is currently unprofitable.

Growing Profit Margin: FBIO is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: FBIO is unprofitable, and losses have increased over the past 5 years at a rate of 13.5% per year.

Accelerating Growth: Unable to compare FBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: FBIO has a negative Return on Equity (-9713.55%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.